ABSTRACT
BACKGROUND: Melatonin reduces the development of breast cancer interfering with oestrogen-signalling pathways, and also inhibits aromatase activity and expression. Our objective was to study the promoters through which melatonin modifies aromatase expression, evaluate the ability of melatonin to regulate cyclooxygenases and assess whether the effects of melatonin are related to its effects on intracellular cAMP, in MCF-7 cells. METHODS: Total aromatase mRNA, aromatase mRNA promoter regions and cyclooxygenases mRNA expression were determined by real-time RT-PCR. PGE(2) and cAMP were measured by kits. RESULTS: Melatonin downregulated the gene expression of the two major specific aromatase promoter regions, pII and pI.3, and also that of the aromatase promoter region pI.4. Melatonin 1 nM was able to counteract the stimulatory effect of tetradecanoyl phorbol acetate on PGE(2) production and inhibit COX-2 and COX-1 mRNA expression. Melatonin 1 nM elicited a parallel time-dependent decrease in both cyclic AMP formation and aromatase mRNA expression. CONCLUSIONS: This study shows that melatonin inhibits aromatase activity and expression by regulating the gene expression of specific aromatase promoter regions. A possible mechanism for these effects would be the regulation by melatonin of intracellular cAMP levels, mediated by an inhibition of cyclooxygenase activity and expression.
Subject(s)
Aromatase/genetics , Breast Neoplasms/enzymology , Gene Expression Regulation, Enzymologic/drug effects , Melatonin/pharmacology , Promoter Regions, Genetic , Prostaglandin-Endoperoxide Synthases/genetics , Breast Neoplasms/pathology , Cell Line, Tumor , Cyclic AMP/analysis , Dinoprostone/biosynthesis , Female , Humans , Prostaglandin-Endoperoxide Synthases/metabolism , RNA, Messenger/analysisABSTRACT
Melatonin exerts oncostatic effects on different kinds of tumors, especially on hormone-dependent breast cancer. The general conclusion is that melatonin, in vivo, reduces the incidence and growth of chemically-induced mammary tumors in rodents, and, in vitro, inhibits the proliferation and invasiveness of human breast cancer cells. Both studies support the hypothesis that melatonin inhibits the growth of breast cancer by interacting with estrogen-signaling pathways through three different mechanisms: (a) the indirect neuroendocrine mechanism which includes the melatonin down-regulation of the hypothalamic-pituitary-reproductive axis and the consequent reduction of circulating levels of gonadal estrogens, (b) direct melatonin actions at tumor cell level by interacting with the activation of the estrogen receptor, thus behaving as a selective estrogen receptor modulator (SERM), and (c) the regulation of the enzymes involved in the biosynthesis of estrogens in peripheral tissues, thus behaving as a selective estrogen enzyme modulator (SEEM). As melatonin reduces the activity and expression of aromatase, sulfatase and 17beta-hydroxysteroid dehydrogenase and increases the activity and expression of estrogen sulfotransferase, it may protect mammary tissue from excessive estrogenic effects. Thus, a single molecule has both SERM and SEEM properties, one of the main objectives desired for the breast antitumoral drugs. Since the inhibition of enzymes involved in the biosynthesis of estrogens is currently one of the first therapeutic strategies used against the growth of breast cancer, melatonin modulation of different enzymes involved in the synthesis of steroid hormones makes, collectively, this indolamine an interesting anticancer drug in the prevention and treatment of estrogen-dependent mammary tumors.
Subject(s)
Breast Neoplasms/enzymology , Melatonin/pharmacology , Neoplasms, Hormone-Dependent/enzymology , Selective Estrogen Receptor Modulators/pharmacology , 17-Hydroxysteroid Dehydrogenases/drug effects , 17-Hydroxysteroid Dehydrogenases/metabolism , Aromatase/drug effects , Aromatase/metabolism , Breast Neoplasms/physiopathology , Estrogens/physiology , Humans , Melatonin/physiology , Neoplasms, Hormone-Dependent/physiopathology , Sulfatases/drug effects , Sulfatases/metabolismABSTRACT
Melatonin exerts oncostatic effects on different kinds of neoplasias, especially on estrogen-dependent mammary tumors. Current knowledge about the mechanisms by which melatonin inhibits the growth of breast cancer cells point to an interaction of melatonin with estrogen-responsive pathways. The intratumoral production of estrogens in breast carcinoma tissue plays a pivotal role in the proliferation of mammary tumoral cells and its blockade is one of the main objectives of the treatment of breast cancer. The aim of the present work is centered on the study of the role of melatonin in the control of some enzymes involved in the formation and transformation of estrogens in human breast cancer cells. The present study demonstrates that melatonin, at physiologic concentrations, modulates the synthesis and transformation of biologically active estrogens in MCF-7 cells, through the inhibition of sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) activity and expression, enzymes involved in the estradiol formation in breast cancer cells. Physiologic concentrations of melatonin also stimulate the activity and expression of estrogen sulfotransferase (EST), the enzyme responsible for the formation of the biologically inactive estrogen sulfates. The level of EST mRNA steady-state of cells treated with melatonin was three times higher than that in control cells. These findings which document that melatonin has an inhibitory effect on STS and 17beta-HSD1 and a stimulatory effect on EST, in combination with its previously described antiaromatase effect, can open up new and interesting possibilities in clinical applications of melatonin in breast cancer.
Subject(s)
Breast Neoplasms/enzymology , Estrogens/biosynthesis , Melatonin/physiology , 17-Hydroxysteroid Dehydrogenases/antagonists & inhibitors , Cell Line, Tumor , Humans , Neoplasms, Hormone-Dependent/enzymology , Steryl-Sulfatase/antagonists & inhibitors , Sulfotransferases/metabolismABSTRACT
Melatonin exerts oncostatic effects on different kinds of neoplasias, especially on oestrogen-dependent tumours. Recently, it has been described that melatonin, on the basis of its antioxidant properties, inhibits the growth of glioma cells. Glioma cells express oestrogen receptors and have the ability to synthesise oestrogens from androgens. In the present study, we demonstrate that pharmacological concentrations of melatonin decreases the growth of C6 glioma cells and reduces the local biosynthesis of oestrogens, through the inhibition of aromatase, the enzyme that catalyses the conversion of androgens into oestrogens. These results are supported by three types of evidence. Firstly, melatonin counteracts the growth stimulatory effects of testosterone on glioma cells, which is dependent on the local synthesis of oestrogens from testosterone. Secondly, we found that melatonin reduces the aromatase activity of C6 cells, measured by the tritiated water release assay. Finally, by (RT)-PCR, we found that melatonin downregulates aromatase mRNA steady-state levels in these glioma cells. We conclude that melatonin inhibits the local production of oestrogens decreasing aromatase activity and expression. By analogy to the implications of aromatase in other forms of oestrogen-sensitive tumours, it is conceivable that the modulation of the aromatase by pharmacological melatonin may play a role in the growth of glioblastomas.
Subject(s)
Aromatase/drug effects , Aromatase/metabolism , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/pharmacology , Glioma/enzymology , Melatonin/administration & dosage , Melatonin/pharmacology , Animals , Down-Regulation/drug effects , Estrogens/biosynthesis , Gene Expression Regulation, Enzymologic/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Glioma/drug therapy , Rats , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, CulturedABSTRACT
OBJECTIVE: The study in ovariectomized (Ovx) rats, as a model of menopausal status, of the effects of melatonin (M) and/or estradiol (E), associated or not with food restriction, on body weight (BW) and serum leptin levels. METHODS: Female SD rats (200-250 g) were Ovx and treated with E, M, E+M or its diluents. Control sham-Ovx rats were treated with E-M diluents. After 7 weeks being fed ad libitum, the animals were exposed for 7 more weeks to a 30% food restriction. We measured: food intake, BW, nocturnal and diurnal urinary excretion of sulphatoxymelatonin (aMT6s), leptin in midday and midnight blood samples, glucose, total cholesterol, LDL, HDL and triglycerides. RESULTS: Day/night rhythm of aMT6s excretion was preserved in all cases. The increase of aMT6s excretion in M-treated animals basically affected the nocturnal period. In animals fed ad libitum, E fully prevented Ovx-induced increase of BW, leptin and cholesterol. Melatonin reduced food intake and partially prevented the increase of BW and cholesterol, without changing leptin levels. Under food restriction, M was the most effective treatment in reducing BW and cholesterol. Leptin levels were similar in M, E or E+M treated rats, and lower than in untreated Ovx rats. CONCLUSIONS: Our result gives a preliminary experimental basis for a post-menopausal co-treatment with estradiol and melatonin. It could combine the effectiveness of estradiol (not modified by melatonin) with the positive effects of melatonin (improvement of sleep quality, prevention of breast cancer, etc.). The possible beneficial effects of melatonin which could justify its use, need to be demonstrated in clinical trials.
Subject(s)
Body Weight/drug effects , Eating/drug effects , Estradiol Congeners/pharmacology , Leptin/blood , Melatonin/pharmacology , Ovariectomy , Analysis of Variance , Animals , Cholesterol/blood , Disease Models, Animal , Female , Obesity/metabolism , Random Allocation , Rats , Rats, Sprague-DawleyABSTRACT
Cadmium (Cd) is a heavy metal classified as a human carcinogen. Occupational exposure, dietary consumption and cigarette smoking are sources of Cd contamination. Cd-induced carcinogenicity depends on its oxidative and estrogenic actions. A possible role of Cd in breast cancer etiology has been recently suggested. Melatonin, because of its antioxidant and antiestrogenic properties could counteract the toxic effects of this metalloestrogen. Our aim was both to determine the effects of relevant doses of Cd on mice mammary glands and uterus and to test whether melatonin would counteract its effects. Female mice of different ages and estrogenic status (prepuberal, adult intact, adult ovariectomized) were treated with CdCl(2) (2-3 mg/kg, i.p.), melatonin (10 microg/mL in drinking water), CdCl(2) + melatonin, or diluents. Whereas in prepuberal animals Cd disturbs mammary ductal growth and reduces the number of terminal end buds, in adults, regardless of the steroidal milieu, Cd exerts estrogenic effects on mammary glands, increasing lobuloalveolar development and ductal branching. Uterine weight also increased as a result of Cd treatment. The effects of Cd are partially inhibited by melatonin. In adult ovariectomized mice, Cd concentration in blood of animals treated with CdCl(2) + melatonin was lower than in mice receiving only Cd; the opposite effects were found in non-castrated animals. As Cd mimics the effect of estrogens, the high incidence of breast cancer in tobacco smokers and women working in industries related with Cd could be explained because of the properties of this metal. The effects of melatonin point to a possible role of this indoleamine as a preventive agent for environmental or occupational Cd contamination.
Subject(s)
Cadmium/toxicity , Mammary Glands, Animal/drug effects , Melatonin/pharmacology , Uterus/drug effects , Animals , Cadmium/antagonists & inhibitors , Environmental Pollutants/antagonists & inhibitors , Environmental Pollutants/toxicity , Estrogens, Non-Steroidal/antagonists & inhibitors , Estrogens, Non-Steroidal/toxicity , Female , Humans , Mammary Glands, Animal/pathology , Mice , Uterus/pathologyABSTRACT
A major mechanism through which melatonin reduces the development of breast cancer is based on its anti-estrogenic actions by interfering at different levels with the estrogen-signalling pathways. Melatonin inhibits both aromatase activity and expression in vitro (MCF-7 cells) as well as in vivo, thus behaving as a selective estrogen enzyme modulator. The objective of this study was to study the effect of MT1 melatonin receptor overexpression in MCF-7 breast cancer cells on the aromatase-suppressive effects of melatonin. Transfection of the MT1 melatonin receptor in MCF-7 cells significantly decreased aromatase activity of the cells and MT1-transfected cells showed a level of aromatase activity that was 50% of vector-transfected MCF-7 cells. The proliferation of estrogen-sensitive MCF-7 cells in an estradiol-free media but in the presence of testosterone (an indirect measure of aromatase activity) was strongly inhibited by melatonin in those cells overexpressing the MT1 receptor. This inhibitory effect of melatonin on cell growth was higher on MT1 transfected cells than in vector transfected ones. In MT1-transfected cells, aromatase activity (measured by the tritiated water release assay) was inhibited by melatonin (20% at 1 nM; 40% at 10 microM concentrations). The same concentrations of melatonin did not significantly influence the aromatase activity of vector-transfected cells. MT1 melatonin receptor transfection also induced a significant 55% inhibition of aromatase steady-state mRNA expression in comparison to vector-transfected MCF-7 cells (p<0.001). In addition, in MT1-transfected cells melatonin treatment inhibited aromatase mRNA expression and 1 nM melatonin induced a higher and significant down-regulation of aromatase mRNA expression (p<0.05) than in vector-transfected cells. The findings presented herein point to the importance of MT1 melatonin receptor in mediating the oncostatic action of melatonin in MCF-7 human breast cancer cells and confirm MT1 melatonin receptor as a major mediator in the melatonin signalling pathway in breast cancer.
Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Aromatase , Breast Neoplasms/enzymology , Melatonin/pharmacology , Receptor, Melatonin, MT1/metabolism , Aromatase/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Down-Regulation , Humans , RNA, Messenger/metabolism , Receptor, Melatonin, MT1/geneticsABSTRACT
Cadmium (Cd) is a heavy metal affecting human health both through environmental and occupational exposure. There is evidence that Cd accumulates in several organs and is carcinogenic to humans. In vivo, Cd mimics the effect of estrogens in the uterus and mammary gland. In estrogen-responsive breast cancer cell lines, Cd stimulates proliferation and can also activate the estrogen receptor independent of estradiol. The ability of this metalloestrogen to increase gene expression in MCF7 cells is blocked by anti-estrogens suggesting that the activity of these compounds is mediated by ER alpha. The aims of this work were to test whether melatonin inhibits Cd-induced proliferation in MCF7 cells, and also to study whether melatonin specifically inhibits Cd-induced ER alpha transactivation. We show that melatonin prevents the Cd-induced growth of synchronized MCF7 breast cancer cells. In transient transfection experiments, we prove that both ER alpha- and ER beta-mediated transcription are stimulated by Cd. Melatonin is a specific inhibitor of Cd-induced ER alpha-mediated transcription in both estrogen response elements (ERE)- and AP1-containing promoters, whereas ER beta-mediated transcription is not inhibited by the pineal indole. Moreover, the mutant ER alpha-(K302G, K303G), unable to bind calmodulin, is activated by Cd but becomes insensitive to melatonin treatment. These results proved that melatonin inhibits MCF7 cell growth induced by Cd and abolishes the stimulatory effect of the heavy metal in cells expressing ER alpha at both ERE-luc and AP1-luc sites. We can infer from these experiments that melatonin regulates Cd-induced transcription in both ERE- and AP1 pathways. These results also reinforce the hypothesis of the anti-estrogenic properties of melatonin as a valuable tool in breast cancer therapies.
Subject(s)
Breast Neoplasms/pathology , Cadmium/pharmacology , Cell Proliferation/drug effects , Estrogen Receptor alpha/antagonists & inhibitors , Melatonin/pharmacology , Cell Line, Tumor , Estrogen Receptor Modulators/pharmacology , Estrogen Receptor alpha/genetics , Humans , Transcriptional Activation/drug effectsABSTRACT
BACKGROUND: Interest in the study of body composition in childhood is increasing. Bioelectrical impedance analysis (BIA) is an accurate and reliable method. OBJECTIVES: To determine anthropometric parameters, fat-free body mass and fat body mass using BIA and anthropometry, and to establish their relationship. MATERIAL AND METHOD: A total of 365 healthy children (188 boys, 177 girls) aged 6.0 to 14.9 years were studied. Weight, height, arm circumference, skinfolds (bicipital, tricipital, subscapular and suprailiac) and bioelectrical parameters were measured. Body density was calculated from the four skinfold measurements using Brook's formula. Bioelectrical impedance was measured with a BIA-101 S (RJL Systems) using a fixed frequency (50 kHz). Fat-free body mass from BIA was calculated using Deurenberg's equation (FFM = 0.82 x height2/resistance). RESULTS: We present the mean, standard deviation and 3rd, 5th, 10th, 25th, 50th, 75th, 90th, 95th and 97th percentiles of anthropometric variables and fat mass and fat-free mass estimated using BIA. Correlations were found between fat-free mass estimated using BIA and anthropometric variables. The reliability of BIA in estimating fat mass was assessed with intraclass correlation coefficients, which were excellent (0.948 in boys, and 0.945 in girls). CONCLUSIONS: BIA is an easy, low-cost, and highly reliable method, making it a useful technique for studying human body composition. This method shows excellent correlation with anthropometric variables.
Subject(s)
Anthropometry , Body Composition , Electric Impedance , Adolescent , Child , Female , Humans , MaleABSTRACT
Antecedentes. El estudio de la composición corporal en la infancia tiene un interés creciente. El análisis de la impedancia bioeléctrica (BIA) es un método fiable y reproducible. Objetivos. Determinar los parámetros antropométricos, la masa magra y grasa mediante BIA y antropometría, y sus relaciones. Material y método. Se estudiaron 365 niños sanos (188 varones y 177 mujeres) de edades entre los 6,0 y 14,9 años. Se midió: peso, talla, perímetro braquial, pliegues cutáneos (bicipital, tricipital, subescapular y suprailíaco) y parámetros bioeléctricos. La densidad corporal se calculó a partir de las medidas de los cuatro pliegues con la fórmula de Brook. La impedancia bioeléctrica se midió con un BIA-101 S (RJL Systems) que usa una frecuencia fija (50 kHz). La masa magra por BIA se calculó con la ecuación de Deurenberg (MM=0,82 x talla2/resistencia).Resultados. Se presentan la media, desviación estándar y percentiles 3, 5, 10, 25, 50, 75, 90, 95 y 97, de los parámetros antropométricos y de la masa magra y grasa estimadas por BIA. Se encontraron correlaciones de la masa grasa por BIA con los parámetros antropométricos. La fiabilidad del BIA para estimar la masa grasa se evaluó mediante el cálculo del coeficiente de correlación interclase, que fueron excelentes (0,948 en varones y 0,945 en mujeres). Conclusiones. El BIA es una técnica de fácil manejo, bajo coste y alta fiabilidad por lo que es muy útil para el estudio de la composición corporal humana y posee una excelente correlación con los parámetros antropométricos (AU)
Subject(s)
Adolescent , Humans , Female , Child , Male , Electric Impedance , Anthropometry , Body CompositionABSTRACT
Melatonin is an indolic hormone produced mainly by the pineal gland. The former hypothesis of its possible role in mammary cancer development was based on the evidence that melatonin down-regulates some of the pituitary and gonadal hormones that control mammary gland development and which are also responsible for the growth of hormone-dependent mammary tumors. Furthermore, melatonin could act directly on tumoral cells, as a naturally occurring antiestrogen, thereby influencing their proliferative rate. The first reports revealed a low plasmatic melatonin concentration in women with estrogen receptor (ER)-positive breast tumors. However, later studies on the possible role of melatonin on human breast cancer have been scarce and mostly of an epidemiological type. These studies described a low incidence of breast tumors in blind women as well as an inverse relationship between breast cancer incidence and the degree of visual impairment. Since light inhibits melatonin secretion, the relative increase in the melatonin circulating levels in women with a decreased light input could be interpreted as proof of the protective role of melatonin on mammary carcinogenesis. From in vivo studies on animal models of chemically induced mammary tumorigenesis, the general conclusion is that experimental manipulations activating the pineal gland or the administration of melatonin lengthens the latency and reduces the incidence and growth rate of mammary tumors, while pinealectomy usually has the opposite effects. Melatonin also reduces the incidence of spontaneous mammary tumors in different kinds of transgenic mice (c-neu and N-ras) and mice from strains with a high tumoral incidence. In vitro experiments, carried out with the ER-positive MCF-7 human breast cancer cells, demonstrated that melatonin, at a physiological concentration (1 nM) and in the presence of serum or estradiol: (a) inhibits, in a reversible way, cell proliferation, (b) increases the expression of p53 and p21WAF1 proteins and modulates the length of the cell cycle, and (c) reduces the metastasic capacity of these cells and counteracts the stimulatory effect of estradiol on cell invasiveness; this effect is mediated, at least in part, by a melatonin-induced increase in the expression of the cell surface adhesion proteins E-cadherin and beta(1)-integrin. The direct oncostatic effects of melatonin depends on its interaction with the tumor cell estrogen-responsive pathway. In this sense it has been demonstrated that melatonin down-regulates the expression of ERalpha and inhibits the binding of the estradiol-ER complex to the estrogen response element (ERE) in the DNA. The characteristics of melatonin's oncostatic actions, comprising different aspects of tumor biology as well as the physiological doses at which the effect is accomplished, give special value to these findings and encourage clinical studies on the possible therapeutic value of melatonin on breast cancer.
Subject(s)
Breast Neoplasms/drug therapy , Melatonin/pharmacology , Neoplasms, Hormone-Dependent/drug therapy , Animals , Antineoplastic Agents/pharmacology , Female , Humans , Mice , Tumor Cells, Cultured/drug effectsABSTRACT
The effects of melatonin on the growth of two highly tumorigenic rodent melanoma cells were studied in vitro. PG19, an amelanotic mouse melanoma cell line, and B16BL6, a melanotic melanoma cell line selected for its invasive potential in vitro, were cultured in the presence of different concentrations of melatonin (10 microM to 0.1 pM). Five days later, viable cells were determined in a haemocytometer by the trypan blue exclusion test. Melatonin at concentrations of 1 nM and 10 pM (within the range of concentrations that correspond to physiological night-time and daytime levels in human blood) significantly inhibited proliferation in both melanoma cell lines. Subphysiological (0.1 pM) or supraphysiological (10 microM to 100 nM) concentrations of melatonin lacked this effect. These results support the hypothesis that, at physiological concentrations, melatonin exerts a direct inhibitory effect on PG19 and B16BL6 cells proliferation.
Subject(s)
Melatonin/therapeutic use , Animals , Coloring Agents/pharmacology , Dose-Response Relationship, Drug , Humans , Melanoma, Experimental , Mice , Neoplasm Metastasis , Trypan Blue/pharmacology , Tumor Cells, CulturedABSTRACT
Melatonin exerts a direct antiproliferative effect on estrogen-responsive MCF-7 cells in culture. Recently, the importance of the anti-invasive actions of melatonin as a part of the oncostatic action of this indolamine has been reported. Gap junctional intercellular communication is known to be involved in controlling cell proliferation and differentiation, and a decrease in intercellular junctional communication has been described in highly invasive mammary cancer cells. Because melatonin at physiological doses (1 nM) shifts MCF-7 cells to a lower invasive status, we postulate that melatonin could modulate the levels of gap junctional intercellular communication in these tumor cells. To test our hypothesis, we studied gap junctional intercellular communication in MCF-7 human breast cancer cells previously (7-8 days) treated, or not, with melatonin (10 microM or 1 nM). Using the scrape-loading assay dye-transfer technique to introduce 0.05% Lucifer yellow into cells, we measured the ability of the tumor cells to transfer dye to adjacent cells. Rhodamine dextran (0.05%) was used as a control dye to verify that dye-transfer occurs through intercellular junctions. The presence of melatonin (10 microM or 1 nM) in the culture medium significantly increased (P < 0.01) the transfer of the dye to adjacent cells through gap junctions. This increase was greater at 10 microM melatonin, and averaged scan profiles of cells treated with melatonin 10 microM showed a statistically significant increase (P < 0.01) in the integrated optical density values, and a broadening of the densitometric scan. These findings suggest that melatonin could exert its antitumor action, at least in part, by increasing regulatory signals that are passed between adjacent epithelial cells through intercellular junctions.
Subject(s)
Cell Communication/drug effects , Gap Junctions/drug effects , Melatonin/pharmacology , Tumor Cells, Cultured/drug effects , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Dextrans/metabolism , Female , Fluorescent Dyes/metabolism , Gap Junctions/metabolism , Humans , Isoquinolines/metabolism , Rhodamines/metabolism , Tumor Cells, Cultured/metabolismABSTRACT
We studied whether human breast cancer cells show increased sensitivity to the chemotherapeutic agent taxol when they have been treated with low radiation doses (1.7-3.2 x 10(-3) Gy) from the gas radon. To this end, MCF-7 cells were cultivated in a medium either with or without dissolved radon for 3 days and then exposed to taxol (50 nM). Cells exposed to low doses of radon and then to a concentration of 50 nM of taxol exhibit a lower proliferation rate and a lower viability than cells treated with the same concentration of taxol but not irradiated. These findings indicate an important interaction of radon and taxol in the inhibition of MCF-7 cell growth.
Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Paclitaxel/pharmacology , Radon/pharmacology , Breast Neoplasms/pathology , Cell Division/drug effects , Cell Division/radiation effects , Cell Survival/drug effects , Cell Survival/radiation effects , Combined Modality Therapy , Dose-Response Relationship, Radiation , Drug Screening Assays, Antitumor , Humans , Tumor Cells, CulturedABSTRACT
Sera from women healthy (HW) or with breast (BCW), ovarian or endometrial cancer, were added (10%) to the culture media of MCF-7 cells and cell proliferation assessed 4 days later to verify: a) whether sera from BCW, obtained before or 8 days after tumor ablaction, influence the proliferation of these cells, b) whether the effects of serum from BCW are specific for mammary tumor cells. Sera from BCW, but not sera from women with ovarian or endometrial cancer, increased MCF-7 cell proliferation in comparison with sera from HW. After surgical ablation of the breast tumors, serum's ability to increase MCF-7 cell proliferation decreased significantly. These effects cannot be explained by differences on serum levels of estradiol or melatonin. These results suggest the presence of growth-promoting substances of possible tumoral origin in serum of BCW, a fact that should be considered as support for the surgical treatment of tumor masses.
Subject(s)
Adenocarcinoma, Papillary/blood , Breast Neoplasms/blood , Neoplasms, Ductal, Lobular, and Medullary/blood , Adenocarcinoma, Papillary/classification , Adenocarcinoma, Papillary/surgery , Breast Neoplasms/classification , Breast Neoplasms/surgery , Cell Division , Culture Media , Endometrial Neoplasms/blood , Estradiol/blood , Female , Health Status , Humans , Melatonin/blood , Neoplasms, Ductal, Lobular, and Medullary/classification , Neoplasms, Ductal, Lobular, and Medullary/surgery , Ovarian Neoplasms/blood , Tumor Cells, CulturedABSTRACT
The role of the pineal as an oncostatic gland has been studied in animal models of tumorigenesis, especially on those concerning the mammary gland. The general conclusion is that experimental manipulations activating pineal gland, or the administration of melatonin, reduce the incidence and growth rate of chemically-induced murine mammary tumors, while pinealectomy or situations which implicate a reduction of melatonin production usually stimulate mammary carcinogenesis. The direct actions of melatonin on mammary tumors have been suggested because of its ability to inhibit, at physiological doses (1nM), the in vitro proliferation of MCF-7 human breast cancer cells. In this article we review the outstanding findings related to melatonin actions on mammary which, taken together, support a possible usefulness of this indoleamine in the prevention and treatment of mammary gland malignancy.
Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/prevention & control , Breast Neoplasms/therapy , Melatonin/pharmacology , Animals , Antineoplastic Agents/therapeutic use , Breast Neoplasms/physiopathology , Disease Susceptibility , Female , Humans , Mammary Glands, Animal , Melatonin/therapeutic useABSTRACT
In this article we review the state of the art on the role of the pineal gland and melatonin in mammary cancer tumorigenesis in vivo as well as in vitro. The former hypothesis of a possible role of the pineal gland in mammary cancer development was based on the evidence that the pineal, via its main secretory product, melatonin, downregulates some of the pituitary and gonadal hormones which control mammary gland development and are also responsible for the growth of hormone-dependent mammary tumors. Furthermore, melatonin could act directly on tumoral cells, thereby influencing their proliferative rate. Other possible origins of melatonin's antitumoral actions could be found in its antioxidant or immunoenhancing properties. The working hypotheses of most experiments were that the activation of the pineal gland, or the administration of melatonin, should give rise to antitumoral behavior; conversely, suppression of the pineal gland or melatonin deficits should stimulate mammary tumorigenesis. From in vivo studies on animal models of tumorigenesis, the general conclusion is that experimental manipulations activating the pineal gland, or the administration of melatonin, enlarge the latency and reduce the incidence and growth rate of chemically induced mammary tumors, while pinealectomy usually has the opposite effects. The direct actions of melatonin on mammary tumors have been suggested because of its ability to inhibit, at physiological doses (1 nM), the in vitro proliferation and invasiveness of MCF-7 human breast cancer cells. The fact that most studies have been performed on two models, chemically induced mammary adenocarcinoma in rats (in vivo studies) and the cell tumor line MCF-7 (in vitro studies), makes the generalization of the results somewhat difficult. However, the characteristics of these actions, comprising different aspects of tumor biology such as initiation, proliferation, and metastasis, as well as the doses (physiological range) at which the effect is accomplished, give special value to these findings. On the strength of these data, the small number of clinical studies focusing on the possible therapeutic value of melatonin on breast cancer is surprising.
Subject(s)
Mammary Neoplasms, Experimental , Melatonin/physiology , Animals , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Cell Division/drug effects , Female , Humans , Mammary Neoplasms, Experimental/physiopathology , Mammary Neoplasms, Experimental/prevention & control , Melatonin/pharmacology , Melatonin/therapeutic use , Pineal Gland/physiopathology , Tumor Cells, CulturedABSTRACT
The aim of the present work was to study whether melatonin, at physiological concentrations, exerts its antiproliferative effects on MCF-7 human breast cancer cells by inducing the expression of some of the proteins involved in the control of the cell cycle. MCF-7 cells were cultured for 48 h in DMEM media containing either melatonin (1 nM) or the diluent (0.001% ethanol). At this concentration, after 48 hours of incubation, melatonin reduced the number of viable cells in relation to controls. The decreased cell proliferation was coincident with a significant increase in the expression of p53 as well as p21WAF1 proteins. These results demonstrate that melatonin inhibits MCF-7 cell proliferation by inducing an arrest of cell cycle dependent on an increased expression of p21WAF1 protein, which is mediated by the p53 pathway.
Subject(s)
Breast Neoplasms/metabolism , Cyclins/biosynthesis , Melatonin/pharmacology , Tumor Suppressor Protein p53/biosynthesis , Breast Neoplasms/drug therapy , Cell Cycle/drug effects , Cell Division/drug effects , Cyclin-Dependent Kinase Inhibitor p21 , Female , Humans , Immunoenzyme Techniques , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolismABSTRACT
Melatonin, the principal pineal gland hormone, exerts a direct antiproliferative effect on estrogen-responsive MCF-7 cells in culture. The purpose of the current study was to investigate the effects of melatonin on the invasion capacity of MCF-7 cells. In vitro, melatonin at physiological doses (1 nM) reduced (P < 0.001) the invasiveness of tumoral cells measured in Falcon invasion chambers. Subphysiological (0.1 pM) and pharmacological concentrations (10 microM) of melatonin failed to inhibit cell invasion. Melatonin was also able to block 17beta-estradiol-induced invasion (P < 0.001). Pretreatment of MCF-7 cells with 1 nM melatonin increased the response of tumoral cells to the anti-invasive effects of this indolamine. To explore possible mechanisms by which melatonin reduces invasiveness, we measured the attachment of MCF-7 cells to a basement membrane, the chemotactic response of the cells, and their type IV collagenolytic activity. The presence of melatonin (1 nM) in the culture medium significantly reduced the ability of MCF-7 cells to attach to the basement membrane; this effect was enhanced by pretreating the cells with the same indolamine (P < 0.001). Melatonin also counteracts the stimulatory effects of 17beta-estradiol on cell adhesion (P < 0.001). The chemotactic response of MCF-7 cells also decreased in the presence of 1 nM melatonin, and this melatonin-induced reduction of cell migration was more effective on cells that were previously incubated for 5 days with melatonin than it was on nonpretreated cells (P < 0.001). The simultaneous addition of 17beta-estradiol and melatonin resulted in a significantly lower chemotactic response than that of 17beta-estradiol-treated cells (P < 0.001). However, type IV collagenolytic activity was not influenced by melatonin. Our results demonstrate that melatonin reduces the invasiveness of MCF-7 cells, causing a decrease in cell attachment and cell motility, probably by interacting with the estrogen-mediated mechanisms of MCF-7 cell invasiveness. In addition, we also studied the influence of melatonin on the expression of two cell surface adhesion molecules (E-cadherin and beta1 integrin) and an intermediate filament protein (vimentin), the expression of which has been correlated with the relative invasive capacity of human breast cancer cells. The culture of tumor cells in the presence of melatonin (1 nM) increased the membrane staining for E-cadherin and beta1 integrin as well as the number of E-cadherin and beta1 integrin immunoreactive cells (P < 0.01). Neither control MCF-7 cells nor those treated with melatonin stained for vimentin. Preliminary in vivo experiments carried out on ovariectomized athymic nude mice implanted with 17beta-estradiol pellets and inoculated with 5 x 10(6) MCF-7 cells in the inguinal mammary fat pad suggest that melatonin could decrease the tumorigenicity of these tumor cells. However, these results need further confirmation. Taken together, our results suggest that melatonin shifts MCF-7 human breast cancer cells to a lower invasive status by increasing the beta1 integrin subunit and E-cadherin expression and promoting the differentiation of tumor cells. Finally, our study points out the existence of the anti-invasive actions of melatonin as a part of the oncostatic action of melatonin.
Subject(s)
Antineoplastic Agents , Breast Neoplasms/pathology , Chemotaxis/physiology , Melatonin/pharmacology , Adipose Tissue , Animals , Basement Membrane , Breast Neoplasms/physiopathology , Cadherins/biosynthesis , Cell Adhesion/drug effects , Cell Division , Chemotaxis/drug effects , Collagenases/metabolism , Culture Media, Conditioned , Estradiol/pharmacology , Female , Humans , Integrin beta1/biosynthesis , Mammary Glands, Animal , Matrix Metalloproteinase 9 , Melatonin/physiology , Mice , Mice, Nude , Neoplasm Invasiveness , Neoplasm Metastasis , Vimentin/biosynthesisABSTRACT
Since melatonin has direct inhibitory effects on some tumor cells in vitro, the aim of the present work was to study whether the growth and structural characteristics of the human neuroblastoma cell line SK-N-SH in vitro are influenced by this indoleamine. Concentrations of melatonin of 10(-9) and 10(-11) M significantly inhibited (P < 0.05) cell proliferation. Subphysiological (10(-13) M) or supraphysiological (10(-7) and 10(-5) M) concentrations of melatonin lacked this effect. After 8 days of exposure to melatonin (10(-9) M), cells showed significantly smaller cell and nuclear sizes than control cells. Melatonin-treated cells presented greater neurite outgrowth than control cells. These results support the hypothesis that melatonin, at physiological concentrations, exerts a direct antiproliferative effect on SK-N-SH cells, promoting the differentiation of neuroblastoma cells.